LISLE, Ill., Aug. 31 /PRNewswire/ -- AtCor Medical Holdings Limited (ASX: ACG - News), the developer and marketer of the SphygmoCor® system which measures central blood pressure non-invasively, has completed an agreement with a United States-based pharmaceutical company to supply SphygmoCor systems and clinical trial support services for a US multi-centre clinical trial. The total value of the contract is US$1.48 million.
The clinical trial will take place over an estimated 30 months. Approximately US$1.1 million in revenue will be recognised in the 2007 financial year. Service revenue of approximately US$400,000 will be spread over the life of the contract.
Ross Harricks, AtCor Medical chief executive officer said, “This order is further evidence of growing pharmaceutical research sector adoption of central pressure data as key to determining the true cardiovascular impact of new drugs. In the ASCOT and CAFE trials, central blood pressure measurements were necessary to adequately explain differences in outcomes between the drug regimens studied. Pharmaceutical companies are now turning to SphygmoCor to document the true cardiovascular effects of their compounds. Using SphygmoCor, these companies have the potential to gain market advantage by demonstrating the physiological benefits of new and current drugs, and also to make better-informed go/no go decisions earlier in the drug development process.”
About AtCor
AtCor Medical is the developer of the SphygmoCor technology, which it markets worldwide to the cardiovascular medical sector. SphygmoCor enables, for the first time, non-invasive measurement of central blood pressures and other key heart function parameters. AtCor is listed on the ASX under code ACG.
Source: AtCor Medical Holdings Limited
